ACE-2-like Enzymatic Activity in COVID-19 Convalescent Patients with Persistent

Pulmonary Symptoms Associated with Immunoglobulin

Yufeng Song[1], Frances Mehl[1], Lyndsey M. Muehling[2], Glenda Canderan[2], Kyle Enfield[2],

Jie Sun[3,4], Michael T. Yin[5], Sarah J. Ratcliffe[6], Jeffrey M. Wilson[7], Alexandra Kadl[2,8],

Judith Woodfolk[7,8], Steven L. Zeichner[1,9]*

[1]Department of Pediatrics, University of Virginia, Charlottesville, VA

[2]Department of Medicine, University of Virginia, Charlottesville, VA

[3]Beirne B. Carter Center for Immunology Research, University of Virginia,

Charlottesville, VA

[4]Division of Infectious Disease and International Health, Department of Medicine,

University of Virginia, Charlottesville, VA

[5]Columbia University Vagelos College of Physicians and Surgeons, New York, NY

[6]Division of Biostatistics, Department of Public Health Sciences, University of Virginia,

Charlottesville, VA

[7]Division of Allergy and Clinical Immunology, Department of Medicine, University of

Virginia, Charlottesville, VA

[8]Department of Pharmacology, University of Virginia, Charlottesville, VA

[9]Department of Microbiology, Immunology, and Cancer Biology, University of Virginia,

Charlottesville, VA

*Correspondence: zeichner@virginia.edu

Abstract

Many difficult to understand clinical features characterize COVID-19 and Post-Acute

Sequelae of COVID-19 (PASC or Long COVID, LC). These can include blood pressure

instability, hyperinflammation, coagulopathies, and neuropsychiatric complaints. The

pathogenesis of these features remains unclear. The SARS-CoV-2 Spike protein

Receptor Binding Domain (RBD) binds Angiotensin Converting Enzyme 2 (ACE2) on

the surface of host cells to initiate infection. We hypothesized that some patients may

produce anti-RBD antibodies that resemble ACE2 sufficiently to have ACE2-like

catalytic activity, that is they are ACE2-like proteolytic abzymes that may help mediate

the pathogenesis of COVID-19 and LC. In previous work, we showed that some acute

COVID-19 patients had immunoglobulin-associated ACE2-like proteolytic activity,

suggesting that some COVID-19 patients indeed produced ACE2-like abzymes.

However, it remained unknown whether ACE2-like abzymes were seen only in acute

COVID-19 patients or whether ACE2-like abzymes could also be identified in

convalescent COVID-19 patients. Here we show that some convalescent COVID-19

patients attending a clinic for patients with persistent pulmonary symptoms also have

ACE2-like abzymes and that the presence of ACE2-like catalytic activity correlates with

alterations in blood pressure in an exercise test.

Introduction

The COVID-19 pandemic has had a devastating effect on world health. An estimated 7M have died so far [1], even with the availability of effective vaccines and antivirals. Beyond COVID-19's acute effect, its long-term effects have had grave effects on individual patients and society. Among the most challenging secondary consequences of COVID-19 are patients affected by Post-Acute Sequelae of COVID-19 (PASC, or Long COVID, LC), reviewed in [2-4], which may affect as many as 7% of COVID-19 patients [5]. Many studies have described the epidemiology and clinical manifestations of LC, and associated LC with various clinical findings, but no clear fundamental, causal mechanisms have been established [6]. LC symptoms can include post-exertional malaise, fatigue, "brain fog" and other neuropsychiatric symptoms, dizziness, GI complaints, cardiovascular complaints like palpitations, libido changes, alterations in smell or taste, cough, chest pain, and abnormal movements [7]. Many LC patients exhibit abnormal clinical features, including blood pressure dysregulation, coagulopathies, and inflammation. [8, 9]. Patients with LC have been found to have distinct immune profiles compared to matched subjects without LC, including altered populations of lymphoid and myeloid cells, altered levels of immune mediators and hormones and increased humoral immune responses against SARS-CoV-2 [10]. Proteomic studies have shown that LC patients have evidence of persistent activation of the complement (C') system with increased concentrations of complement proteolysis products and proteolysis by thrombin [11], but these findings have not identified a proximate cause underlying the disease. Since no proximate cause of LC has been identified, no specific therapies are available, and these patients continue to suffer and are treated only with non-specific therapies directed at one or another symptom.

We noted that proteolytic regulatory cascades control many of the physiologic pathways dysregulated in COVID-19 and LC, such as blood pressure regulation (angiotensin), coagulation (thrombin), and inflammation (C', kallikrein-kinin) [12-14]. Some of the problematic clinical disorders related to COVID-19 do not become apparent until a week or more after infection, so their underlying pathogenesis is likely due to secondary or reactive processes and not due to primary

cytotoxicity from acute viral replication. Additional data suggests that some of the COVID-19-

associated inflammatory processes may involve antibodies against SARS-CoV-2 spike protein,

S. For example, a small number of patients who received SARS-CoV-2 vaccines and had no

evidence of SARS-CoV-2 infection exhibit disordered inflammatory responses, blood pressure

dysregulation or coagulopathy[15]., and a small number of infants born to mothers with COVID-19

have been described as having multi-system inflammatory syndrome of children (MIS-C) [16]

Since many of COVID-19 and LC's puzzling features appear to involve physiologic

regulatory cascades controlled by proteolysis, we considered how infection with SARS-CoV-2

might yield pathologies involving proteolytic regulatory cascades. We noted that angiotensin

converting enzyme 2 (ACE2) is SARS-CoV-2's host cell receptor [17]. ACE2 exists both free in the

circulation and in the membranes of cells of several tissues. While angiotensin converting

enzyme (ACE) cleaves angiotensin I to yield angiotensin II, a vasoconstrictor that increases

blood pressure [18], ACE2 acts in a counter-regulatory fashion to ACE, cleaving angiotensin II to

yield angiotensin 1-7, a vasodilator that lowers blood pressure [19]. We recalled the literature

concerning catalytic antibodies or "abzymes" [20, 21]. When abzymes were first identified,

researchers created abzymes by making anti-idiotypic antibodies against antibodies that

themselves had been produced against the active site of a particular enzyme of interest[22, 23].

Some of the anti-idiotypic antibodies resembled the enzyme's active site sufficiently for the

antibody to have catalytic activity like that of the original enzyme[24, 25]. However, some abzymes

exhibited substrate specificities that differed notably from those of the original enzyme's [23, 24, 26].

The abzymes exhibited substrate promiscuity compared to the original enzyme and had

catalytic activity that was lower than the activity typically seen with more conventional

enzymes ($k$cat/Km values $\sim 10^2$ - 10^4 s^{-1}•M s^{-1} [27] vs. $k$cat/Km values of $\sim 10^5$ s^{-1}•M s^{-1})[28].

The poorer activity, in addition to the problems with substrate specificity spread, led to

decreased interest in abzymes as a new biotechnology.

We hypothesized that some COVID-19 patients may develop antibodies with catalytic

activity because the RBD, since it binds ACE2, should have a partial negative image of ACE2,

so some anti-RBD antibodies may have enough similarity to ACE2 to have proteolytic activity

similar to ACE2, or perhaps other proteolytic enzymes due to substrate specificity spread seen

with abzymes. ACE2 can cleave many peptides with important physiologic activity beyond

angiotensin II [29]

There are examples of patients who produce abzymes with potentially clinically

significant effects, for example DNA [30], immunoglobulin [31], vasoactive intestinal peptide

(VIP)[32], myelin basic protein (MBP) in multiple sclerosis patients [33], and factors in the

coagulation cascade [34-36]. Some patients with HIV have been shown to produce

abzymes that cleave HIV Env, so there exist examples of cases where viral infection

induces production of an abzyme [37].

In previous work [38], we showed that some patients with acute COVID-19

produced antibodies with ACE2-like catalytic activity. However, the question remained

whether antibodies with ACE2-like catalytic activity were present in convalescent

COVID-19 patients and, if so, whether the presence of ACE2-like catalytic activity

correlated with any plausible clinical findings. Here we show results obtained from 20

convalescent COVID-19 patients who attended a clinic at the University of Virginia for

convalescent COVID-19 patients with persistent pulmonary symptoms. Prior work

identified persistent inflammation and immune dysregulation within these individuals,

including auto-reactive antibodies [39]. We found that six of those patients had ACE2-like

antibody-associated catalytic activity in their plasma, and that the presence of ACE2-like

antibody-associated catalytic activity correlated with lower blood pressure after a six-

minute walk test, indicating that ACE2-like abzyme activity occurs in both acute and

convalescent COVID-19 patients and can have associations with physiologic

consequences.

Methods

Clinical Cohort

We studied a subset of individuals from a previously published cohort of COVID-19
convalescent patients at the University of Virginia [39] of COVID-19 convalescent patients
who attended a post-COVID pulmonary clinic for follow-up care (COVID Recovery
Cohort (COVID-RC)). All patients had confirmed prior COVID-19 infection. Twenty
patients, spanning a broad range of anti-Spike IgG levels (2.1-314.6 μg/mL), with
available plasma biospecimen, were selected for abzyme studies. The characteristics of
the patients selected for abzyme studies are listed in Table 1. Most patients were
hospitalized during acute infection (70%), with 30% requiring mechanical ventilation.
Patients initially contracted COVID-19 from March 2020-March 2022, with the majority
becoming infected prior to the circulation of major viral variants (70%). SARS-CoV-2
anti-spike and anti-capsid IgG was measured by ImmunoCAP assay[38, 40]. Approximately
half of the selected subjects (55%) had received at least one SARS-CoV-2 vaccine
dose at the time of sample collection. While there was a statistically significant
association between receipt of at least one dose of vaccine and anti-spike IgG, there
was no significant association between vaccine receipt and the presence of ACE-2-like
catalytic antibodies and no statistically significant association between anti-spike IgG
level and the presence of ACE-2-like catalytic antibodies.

Clinical and Other Data

Clinical data collected from the patients in the cohort included a symptom inventory. A
six-minute walk test was given to 18 of the patients included in this study, in which heart
rate, systolic and diastolic blood pressures were recorded before and after the test walk.
Data on plasma cytokines TNF-α and IL-6 was obtained for 12 patients, as previously

described[39].To explore whether inflammatory cytokine markers might correlate with the

presence of ACE2-like catalytic activity, we examined TNF-α and IL-6 levels for some of

the patients, but found no statistically significant correlations. Table 2 summarizes this

data.

Angiotensin II Converting Enzyme (ACE2)-like Abzyme Activity Detection

Abzyme catalytic activities in plasma samples were measured using an Angiotensin II

Converting Enzyme (ACE2) Activity Assay Kit, Fluorometric (Abcam, Cat. #ab273297)

providing a synthetic ACE2 peptide substrate labeled with a fluor and a quencher with a

lower limit of detection for an unmodified assay of 400 µU as described [38]. Recombinant

human ACE2 (ACE2) as a positive control is also included in the assay kit. ACE2

inhibitor provided in the assay kit was also used for additional controls. Briefly, 50μl

plasma or diluted plasma (in PBS without Ca^{2+} or Mg^{2+}, and with 4mM EDTA added)

was added to wells in a 96-well black flat bottom assay plate (Corning, Cat. #3603) and

incubated at room temperature (RT), in the dark for 15 min. Then, 50μl pre-diluted

substrate was added into the wells of the plate, mixing the substrate with the plasma

sample. The plate was immediately placed into a SpectraMax® M5 multi-model

microplate reader (Molecular Devices). After 3 minutes incubation, the Relative

Fluorescent Unit (RFU, Ex/Em = 320/420 nm) values were measured in kinetic mode

every 20 min for a total of 16 hours at 37℃. We performed assays on normal human

plasma spiked with serial dilutions of rACE2 to determine the lower limits of detection

for the assay (Figure S1). We then defined as a̶ "positive" samples that had RFU slopes

(between 5 and 120 minutes) that were greater than or equal to 2-fold the slope of the

lower limit of detection of serial dilution assays using rACE2 spiked into normal human

plasma.

We conducted negative control experiments using the ACE2 inhibitor from the

assay kit for additional controls.

Human Immunoglobulin Depletion and Detection

We depleted immunoglobulin from the plasma samples as previously described in detail

[38]. Plasma samples were 1:8 diluted in PBS with 4 mM EDTA and centrifuged at 12,000

× g at 4 ℃ for 15 min followed by passing through 0.45 μm syringe filter

(FisherScientific, Cat. #97204). We loaded 500 μL of the filtered samples onto

ultrafiltration columns with 100kDa cut-off ultrafiltration membrane (Pierce™ Cat. #

88503) and centrifuged the columns at 12,000 × g at 4 ℃ until > 400 μL of filtrate was

produced. The flow-through fractions were then incubated with 30 μL pre-washed

Protein A/G Magnetic Beads (Life Technologies, Cat. # 88803, 10 mg/mL) at room

temperature (RT) for 1 hour, and repeated a second time to further deplete the

antibodies. Human IgG was measured using a Human IgG ELISA Kit (Abcam, Cat.

#ab100547) according to the manufacturer's protocol as described [38]. Briefly, 100 μl

samples, as well as standards, were added into each well of multi-microwell strips and

incubated at room temperature for 2.5 hours. Biotin-labeled IgG detection antibody was

then added to each well after wash and incubated at room temperature for 1 hour.

Then, HRP-streptavidin was added at room temperature for 1 hour. After wash, OD

values were developed by adding TMB One-Step Substrate and Stop Solution

subsequently. OD values were read at 450 nm using an accuSkan FC micro-well plate

reader (ThermoFisher). IgG concentrations were calculated based on standard curves

generated with the same batch of assay strips. Our depletion protocol removes

>99.99% of human IgG and IgM from the plasma samples[38].

ACE2 Substrate Peptide Cleavage Competition Inhibition by SARS-CoV-2 Spike

RBD Peptide Pools

As described previously [38] we synthesized tiled SARS-CoV-2 spike protein RBD (receptor binding domain) peptides (SB-PEPTIDE, SmartBioscience SAS, France) from residues Arg319 to Phe541, including receptor binding motif (RBM) from Ser438 to Gln506, based on a published analysis on viral-host interaction [41]. We added 10μg per peptide to selected plasma samples, diluted 1:8 dilution with PBS with 4 mM EDTA. Recombinant human ACE2 protein, supplied in the kit served as a positive control. Sample-peptide pool mixtures were incubated at RT for 15 min in dark before adding the substrate. Samples incubated with ddH$_2$O and DMSO (1:1 mixture), equivalent to the concentrations of the peptide pool reconstitution served as negative controls. Relative Fluorescent Units were measured as described above, and data was analyzed as described below.

Data Analysis

As previously described [38], RFU values observed over 120 min were used to evaluate ACE2 substrate cleavage activities in those plasma samples. Corrected value of each sample was calculated by subtracting baseline RFU value from the value at each subsequent time point and the sum of baseline-corrected value over 120 min was also calculated using R. The change in RFU over the first 120 minutes of the assay was calculated using linear regression and was used as a measure of ACE2-like activity. Correlations between ACE2 like activity and clinical data were assessed using Pearson's product-moment correlation for numerical variables and Kruskal-Wallis rank/sum test for categorical variables. Data analysis and visualization was performed

222   with R (version 2022-06-23) using the Rstudio user interface with packages including

223   ggplot2, tidyverse, readr, drc, ggpubr, ggh4x, stringr, and patchwork.

Results

To determine whether COVID-19 convalescent patients produced antibodies with ACE2-like catalytic activity, similar to those we identified in acute COVID-19 patients [38], we studied samples available from 20 patients from an existing cohort available at the University of Virginia for which plasma samples and clinical testing was available. This cohort, already described[39], enrolled convalescent COVID-19 patients, the majority of whom reported persistent pulmonary symptoms. The demographic characteristics of the cohort are described in Table 1.

We conducted ACE2 activity assays on 20 plasma samples from these patients. We found that 6 of them had ACE2-like catalytic activity greater than or equal to 2-fold above the lower limits of detection for ACE2 as determined by serial dilution experiments using rACE2, our conservative criteria for positive ACE2-like activity. An additional 5 patients had borderline positive ACE2-like activity, with levels greater than or equal to the lower limits of detection of the rACE2, but less than the 2-fold greater than the lower limit of detection cut-off (FIGs 1 and 2).

To determine whether the ACE2-like activity was associated with immunoglobulin in these samples, we conducted an immunoglobulin depletion procedure, that included depleting molecules >100 KDa using a centrifugal ultrafiltration column followed by a protein A/G absorption step. The procedure yielded samples that were depleted in immunoglobulin by >99.9% (Table 3).

We conducted the ACE2-like activity assays on the immunoglobulin-depleted plasma samples from the patients who were found to be positive for ACE2-like activity. The immunoglobulin-depleted samples had no ACE2-like activity, supporting the hypothesis that the ACE2-like activity is antibody-associated (FIG 3).

To further confirm the specificity of the ACE2-like activity, we conducted assays

on the samples in the presence of tiled overlapping peptides that included the RBD site

in the spike protein [38]. Competition with using the overlapping spike RBD region

peptides strongly inhibited the ACE2-like cleavage activity present in the patient plasma

samples, further confirming that the ACE2-like activity was specific for an RBD-

interacting activity of the plasma antibodies. There was a modest decrease when the

competing peptide diluent was added alone, probably because addition of the diluent

increased the volume of the material assayed in the wells (FIG 4).

The cohort studied here consisted of patients with persistent pulmonary

symptoms (complaints of cough, difficulty breathing, or dyspnea on exertion) not

patients enrolled specifically because they had symptoms that could be considered

characteristic for LC. Nevertheless, several patients in this cohort had a variety of

symptoms beyond the strictly pulmonary symptoms. Table 2 lists the range of

symptoms reported in this cohort.

If SARS-CoV-2 infection elicits the production of abzymes, it would be important

to know if those abzymes were associated with any clinical features. Here, we focused

on catalytic antibodies with ACE2-like activity, so for this study our interests centered on

whether there would be a correlation in the patients between ACE2-like catalytic activity

and a physiologic variable that could be related to dysregulated ACE2-like activity.

ACE2 catalyzes the cleavage of the vasoconstrictor angiotensin II to the

counterregulatory vasodilator angiotensin 1-7. A dysregulation of angiotensin 1-7

production might be expected to prevent a patient from maintaining ideal vascular tone.

So, if a patient has an ACE2-like catalytic antibody in the circulation, we hypothesized

that they may experience problems with blood pressure regulation, particularly after an

event that demanded a physiologic response to maintain blood pressure homeostasis,

like an exercise challenge. Thus, we asked whether patients with higher ACE2-like

abzyme activities were less likely to maintain their blood pressures during a 6-minute

walk test. Analysis of data from 18 patients revealed a significant correlation between

the change in systolic blood pressure after 6 minute walk test and ACE2-like activity,

with patients showing higher ACE2-like activity experiencing greater decreases in

systolic blood pressure (r=-0.54, p=0.021). Non-statistically significant trends associated

ACE-2 like catalytic activity with an increase in heart rate after the six-minute walk test

and the absolute systolic blood pressure after six-minute walk test (FIG 5).

Discussion

Our prior work [38] showed that some patients with acute COVID-19 produced antibodies that had ACE2 catalytic activity (ACE2-like abzymes) and that abzyme activity correlated with RBD binding activity. However, that study involved only patients with acute COVID-19, and did not address whether the ACE2-like abzyme activity persisted after resolution of the acute disease into the convalescent period. In this study, we show that some patients convalescing from COVID-19 also have antibodies with ACE2-like abzyme activity, and that the presence of ACE2-like abzyme activity correlates with a physiologically plausible clinical finding, namely decrease in blood pressure after six-minutes of walking.

The finding that patients convalescing from COVID-19 can have circulating ACE2-like abzymes that correlate with a clinical finding supports the hypothesis that post-COVID-19 circulating abzymes could be involved in other aspects of disorders observed in patients convalescing from COVID-19. These could conceivably include some of the clinical features of LC, since many of the clinical problems observed in LC patients include features that can be mediated by proteolytic regulatory cascades, although considerable additional work on larger cohorts with different clinical manifestations of LC, and additional assays for other antibody-associated catalytic activity would be needed to establish such associations. However, the hypothesis is highly testable, able to inform clear, follow-on studies, such as studies to determine if convalescent COVID-19 patients with LC have circulating abzymes that can affect additional proteolytic regulatory cascades capable of mediating one or another aspect of LC pathogenesis. If pathophysiologically active SARS-CoV-2-induced abzymes are found, they could offer a plausible target for the development of new therapies, which

could be useful, since there are no currently available therapies directed at a proximate

cause of LC.

Our study had several strengths. We studied a well-defined cohort of patients,

who had clear, persistent pulmonary symptoms after convalescing from acute COVID-

19. Additional objective clinical and laboratory information was available for these

patients, enabling us to conduct preliminary analyses to determine whether there any

clinical features that correlated with the presence of ACE2-like abzymes. We used a

well-characterized ACE2 peptide substrate cleavage activity kit, and available size

exclusion columns, protein A/G bead absorption immunoglobulin depletion procedures,

and standard, available immunoglobulin assays.

Our study also has several limitations. We studied moderate number of patients

with a single subset of post-COVID-19 clinical complaints, restrictive lung disease [39]. A

much larger study or series of studies, involving many more patients with a variety of

distinct principal manifestations of post-acute COVID-19 symptoms, ideally clearly

defined LC symptomatology and additional, multiple comprehensive assays for

antibody-associated catalytic activity would be needed to firmly support the abzyme

hypothesis, but such work would be outside the scope of this study and samples that

were available to us at the time of the study. The limitation of the cohort to those

patients with lung disease may also have limited any relationships between the

presence of ACE2-like abzyme activity and physiological variables, particularly

cardiovascular variables, since those are influenced by pulmonary disease. The

persistent pulmonary symptoms that define this cohort likely result from many causes,

perhaps most likely direct damage to lung parenchyma by viral replication and the

secondary host inflammatory response. The cohort was not limited to patients who met

a strict LC definition, so while some patients had symptoms that could be characterized

as belonging to the spectrum of LC, other patients in the cohort did not have such

symptoms. Additional studies of a cohort specifically comprised of LC patients would be

needed to determine whether LC symptoms were specifically associated with abzymes

that had one or another catalytic activities. Other factors could certainly mediate the

clinical symptoms that trouble LC patients. It is likely that LC symptoms have more than

one cause. Among those other causes could be SARS-CoV-2 elicited abzymes with

catalytic activities other than ACE2-like catalytic activities, but we were not able to test

for those other activities in this study due to sample quantity constraints.

Finally, to definitively establish that an antibody induced by SARS-COV-2 has

catalytic activity with potentially clinically meaningful effects, it would be necessary to

isolate and study the antibody in pure form, something also outside the scope of this

study.

Nonetheless, our study shows that some COVID-19 convalescent patients make

antibodies with catalytic activity, a useful next step in understanding the pathogenesis of

COVID-19 and LC.

Institutional Review Board Statement: The University of Virginia Institutional Review

Board approved enrollment of all subjects and collection of specimens and related

metadata (HSR #HSR13166).

Informed Consent Statement: Informed consent was obtained from the subjects in the

study.

Data Availability Statement: Data is presented in the manuscript. Raw data is

available upon request.

Acknowledgments and Funding: The study was supported by internal funding from

the University of Virginia, including the Manning Fund for COVID-19 Research at UVA

the Ivy Foundation, the Pendleton Laboratory Fund for Pediatric Infectious Disease

Research, and grants from NIAID, NIH (R01 AI176515, R21 AI138077, R56 AI178669).

We thank the patient volunteers for generously agreeing to be research subjects in the

study, and Deborah Murphy RN who assisted with enrollment of study participants).

Conflicts of Interest: The authors declare no conflict of interest.

Tables
369
370

371 **Table1**

373 Demographic and clinical characteristics of the patients included in the study.

Patient Characteristics (n=20)	
Age(yrs)	54+/-19
Sex	Male (55%), Female (45%)
Race	White (85%), Black (10%), Other (5%)
Days since start of illness	201 +/-129
Hospitalized for Covid	Yes (70%), No (30%)

Table 2.

Symptoms, cytokine assays, and physiologic measurements conducted on the
patients in the study.

For the data listed under the six-Minute Walk Test heading, Pre-HR is the heartrate
before the walk, Post-HR is the heartrate after the walk, Change HR is (PostHR –
PreHR), Pre SBP is the systolic blood pressure before the walk, Post SBP is the systolic
blood pressure after the walk, Change SBP is (Pre SBP – Post SBP), Pre DBP is the
diastolic blood pressure before the walk, Post DBP is the diastolic blood pressure after
the walk, Change DBP is (Pre DBP – Post DBP).

Symptoms	
Pulmonary Symptoms	*Patients with Symptom*
Cough	40%
Breathing Difficulty	10%
Dyspnea on exertion	80%
Other Symptoms	
Headache	10%
Weakness	15%
Fatigue	60%
Dizzy/Lightheaded/Syncope	20%
Brain fog/Memory Problems	35%
Sleep Disruption	45%
Pain	25%
Numbness	15%
Inflammatory Cytokines (n=12)	
TNF-α (pg/mL)	58 +/-52
IL-6 (pg/mL)	3.2 +/-3.2
Six-Minute Walk Test (n=18)	
Pre-HR (beats/minute)	88 +/-12
Post-HR (beats/minute)	111 +/-19
Change HR (beats/minute)	23 +/-13
Pre SBP (mmHg)	137 +/-17
Post SBP (mmHg)	145 +/-23
Change SBP (mmHg)	8 +/-16
Pre DBP (mmHg)	80 +/-8
Post DBP (mmHg)	82 +/-12
Change DBP (mmHg)	2 +/-9

391   **Table 3**
392
393   ***Immunoglobulin depletion following high molecular weight depletion and protein***
394   ***A/G bead absorption.***
395   Assays for the IgG concentration were conducted in triplicate.
396
397

Patient	Plasma IgG Concentration Mean +/-SD		IgG Depletion Efficiency
	Pre-IgG Depletion (mg/ml)	Post-IgG Depletion (ng/ml)	
#1	1.62 +/-0.01	0.19 +/-<0.001	>99.99%
#3	0.40 +/-0.01	0.19 +/-<0.001	>99.99%
#5	1.82 +/-0.02	0.19 +/-<0.001	>99.99%
#9	0.82 +/-0.05	0.19 +/-<0.001	>99.99%
#11	0.53 +/-0.01	0.19 +/-<0.001	>99.99%
#16	0.45 +/-0.08	0.19 +/-0.003	>99.99%
#2	1.03 +/-0.01	0.19 +/-0.000	>99.99%
#20	0.63 +/-0.04	0.19 +/-0.001	>99.99%
#14	1.27 +/-0.02	0.18 +/-0.001	>99.99%
#13	0.60 +/-0.01	0.18 +/-0.001	>99.99%
HDP	2.86 +/-1.72	0.03 +/-0.004	>99.99%

398
399
400
401

FIG 1. ACE-2-Like Activity in Convalescent Patient Plasma

 Assays for ACE2-like enzymatic activity conducted on EDTA-anti-coagulated plasma
 from 20 COVID-19 convalescent patients with persistent pulmonary symptoms,
 conducted with a fluor-quench tagged peptide substrate, as described in [38]. We
 determined the assay slopes over 5-120 minutes and then conservatively called as a
 positive any sample with a 5-120 minute slope greater than twice the slope of the lower
 limit of detection of the positive control (recombinant ACE2) (FIG S1).

FIG 2. Distribution of ACE-2-like activity in the Convalescent Patients

Distribution of the 5-120 minute ACE2-like enzymatic activity slopes from Fig 1, compared to the recombinant humant rACE2 positive control. We found that 6 out of the 20 plasma samples had slopes that we considered positive, with slopes greater than that observed for the rACE2 positive control at twice the lower limit of detection. An additional 5 patients had ACE2-like catalytic activity with 5-120 minute slopes (RFU/min) greater than or equal to the slope observed with rACE2 at the lower limit of detection.

FIG 3. ACE2-like Activity in Patient Samples Depleted of Immunoglobulin

Assays for ACE2-like enzymatic activity conducted on EDTA-anti-coagulated plasma of the 6 out of 20 COVID-19 convalescent patients with persistent pulmonary symptoms positive for ACE2-like activity in FIGs 1 and 2, conducted with a fluor-quench tagged peptide substrate, with immunoglobulins depleted as described in the Methods and [38].

 FIG 4. Inhibition of ACE2-like catalytic activity in plasma from COVID-19
 convalescent patients by pooled tiled RBD peptides.

 Assays for ACE2-like enzymatic activity conducted on EDTA-anti-coagulated plasma
 from 20 COVID-19 convalescent patients with persistent pulmonary symptoms,
 conducted with a fluor-quench tagged peptide substrate, with ACE2 activity competed
 using tiled overlapping RBD peptides as described in [38].

487 **FIG 5. Correlation between cardiovascular six-minute walk stress test variables**
488 **and ACE2-like catalytic activity.**
489
A. Change in systolic blood pressure vs. ACE2-like catalytic activity. B. Change in heart
rate vs. ACE2-like catalytic activity. C. Systolic blood pressure vs. ACE2-like catalytic
activity. The change in systolic BP had a correlation of -0.54, p = 0.021. The changes in
heart rate (correlation -0.29, p = 0.241) and absolute systolic blood pressure after the 6
minute walk (correlation 0.34, p = 0.178) were not significant (Pearson's product
moment correlation).
496
497

498
499

References

1.   Organization WH. WHO COVID-19 dashboard. World Health Organization; 2024 [cited 2024 24 June]; https://data.who.int/dashboards/covid19/deaths.

2.   Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nature Reviews Immunology. 2023;23(10):618-34.

3.   Perumal R, Shunmugam L, Naidoo K, Abdool Karim SS, Wilkins D, Garzino-Demo A, Brechot C, Parthasarathy S, Vahlne A, Nikolich JŽ. Long COVID: a review and proposed visualization of the complexity of long COVID. Frontiers in immunology. 2023;14:1117464.

4.   Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21(3):133-46.

5.   Adjaye-Gbewonyo D, Vahratian A, Perrine CG, Bertolli J. Long COVID in Adults: United States, 2022. 26/2023.

6.   Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, Primus-de Jong C, Cleemput I, Van den Heede K. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022 Dec;54(1):1473-87. PMC9132392

7.   Marchi M, Grenzi P, Serafini V, Capoccia F, Rossi F, Marrino P, Pingani L, Galeazzi GM, Ferrari S. Psychiatric symptoms in Long-COVID patients: a systematic review. Frontiers in Psychiatry. 2023;14:1138389.

8.   Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, McCorkell L, Nadkarni GN, Parthasarathy S, Singh U, Walker TA, Selvaggi CA, Shinnick DJ, Schulte CCM, Atchley-Challenner R, Horwitz LI, Foulkes AS, Authors RC, Consortium R. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329(22):1934-46.

9.   Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022 Apr;22(4):e102-e7. PMC8691845

10.   Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, Tabachnikova A, Greene K, Tabacof L, Malik AA, Silva Monteiro V, Silva J, Kamath K, Zhang M, Dhal A, Ott IM, Valle G, Peña-Hernández M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Song E, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng TJ, Xu L, Geraghty AC, Monje M, Yildirim I, Shon J, Medzhitov R, Lutchmansingh D, Possick JD, Kaminski N, Omer SB, Krumholz HM, Guan L, Dela Cruz CS, van Dijk D, Ring AM, Putrino D, Iwasaki A. Distinguishing features of long COVID identified through immune profiling. Nature. 2023 Nov;623(7985):139-48. PMC10620090

11.   Cervia-Hasler C, Brüningk SC, Hoch T, Fan B, Muzio G, Thompson RC, Ceglarek L, Meledin R, Westermann P, Emmenegger M, Taeschler P, Zurbuchen Y,

Pons M, Menges D, Ballouz T, Cervia-Hasler S, Adamo S, Merad M, Charney AW, Puhan M, Brodin P, Nilsson J, Aguzzi A, Raeber ME, Messner CB, Beckmann ND, Borgwardt K, Boyman O. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science. 2024 Jan 19;383(6680):eadg7942.

12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. PMC7159299

13. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, Gao Y, Cai L, Wang Z, Yin P, Wang Y, Tang L, Deng J, Mei H, Hu Y. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020 Sep;7(9):e671-e8. PMC7351397

14. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020 Oct;26(10):1636-43. PMC7869028

15. Yousaf AR, Cortese MM, Taylor AW, Broder KR, Oster ME, Wong JM, Guh AY, McCormick DW, Kamidani S, Schlaudecker EP, Edwards KM, Creech CB, Staat MA, Belay ED, Marquez P, Su JR, Salzman MB, Thompson D, Campbell AP. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022 Feb 22. PMC8864018

16. De Rose DU, Pugnaloni F, Calì M, Ronci S, Caoci S, Maddaloni C, Martini L, Santisi A, Dotta A, Auriti C. Multisystem Inflammatory Syndrome in Neonates Born to Mothers with SARS-CoV-2 Infection (MIS-N) and in Neonates and Infants Younger Than 6 Months with Acquired COVID-19 (MIS-C): A Systematic Review. Viruses. 2022;14(4):750.

17. Oudit GY, Wang K, Viveiros A, Kellner MJ, Penninger JM. Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic. Cell. 2023 Mar 2;186(5):906-22. PMC9892333

18. Khurana V, Goswami B. Angiotensin converting enzyme (ACE). Clin Chim Acta. 2022 Jan 1;524:113-22.

19. Turner AJ, Nalivaeva NN. Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation. Peptides. 2022 May;151:170766. PMC8830188

596   20.   Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science. 1986 Dec
597   19;234(4783):1566-70.
598
599   21.   Pollack SJ, Jacobs JW, Schultz PG. Selective chemical catalysis by an antibody.
600   Science. 1986 Dec 19;234(4783):1570-3.
601
602   22.   Avalle B, Mistro D, Thomas D, Friboulet A. Polyclonal catalytic anti-idiotypic
603   antibodies with a beta-lactamase activity. Ann N Y Acad Sci. 1996 Oct 12;799:172-5.
604
605   23.   Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Abzyme generation using
606   an anti-idiotypic antibody as the "internal image" of an enzyme active site. Appl
607   Biochem Biotechnol. 1994 May-Jun;47(2-3):229-37; discussion 37-9.
608
609   24.   Izadyar L, Friboulet A, Remy MH, Roseto A, Thomas D. Monoclonal anti-idiotypic
610   antibodies as functional internal images of enzyme active sites: production of a catalytic
611   antibody with a cholinesterase activity. Proc Natl Acad Sci U S A. 1993 Oct
612   1;90(19):8876-80. PMC47463
613
614   25.   Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Antiidiotypic antibodies as
615   functional internal images of enzyme-active sites. Ann N Y Acad Sci. 1995 Mar
616   31;750:265-70.
617
618   26.   Ponomarenko NA, Pillet D, Paon M, Vorobiev, II, Smirnov IV, Adenier H, Avalle
619   B, Kolesnikov AV, Kozyr AV, Thomas D, Gabibov AG, Friboulet A. Anti-idiotypic
620   antibody mimics proteolytic function of parent antigen. Biochemistry. 2007 Dec
621   18;46(50):14598-609.
622
623   27.   Hilvert D. Critical analysis of antibody catalysis. Annu Rev Biochem.
624   2000;69:751-93.
625
626   28.   Bar-Even A, Noor E, Savir Y, Liebermeister W, Davidi D, Tawfik DS, Milo R. The
627   moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme
628   parameters. Biochemistry. 2011 May 31;50(21):4402-10.
629
630   29.   Bernstein KE, Khan Z, Giani JF, Cao DY, Bernstein EA, Shen XZ. Angiotensin-
631   converting enzyme in innate and adaptive immunity. Nat Rev Nephrol. 2018
632   May;14(5):325-36. PMC6192041
633
634   30.   Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov
635   AG. DNA hydrolyzing autoantibodies. Science. 1992 May 1;256(5057):665-7.
636
637   31.   Paul S, Li L, Kalaga R, Wilkins-Stevens P, Stevens FJ, Solomon A. Natural
638   catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL
639   fragment. J Biol Chem. 1995 Jun 23;270(25):15257-61.
640
641   32.   Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic
642   hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989 Jun
643   9;244(4909):1158-62.
644

33. Ponomarenko NA, Durova OM, Vorobiev, II, Belogurov AA, Jr., Kurkova IN,
Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM,
Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC, 3rd, Thomas D,
Friboulet A, Gabibov AG. Autoantibodies to myelin basic protein catalyze site-specific
degradation of their antigen. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):281-6.
PMC1324791

34. Thiagarajan P, Dannenbring R, Matsuura K, Tramontano A, Gololobov G, Paul S.
Monoclonal antibody light chain with prothrombinase activity. Biochemistry. 2000 May
30;39(21):6459-65.

35. Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg JY, Borel-Derlon
A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S. Factor VIII hydrolysis
mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol. 2008 Jun
1;180(11):7714-20.

36. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N,
Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. Catalytic activity of
antibodies against factor VIII in patients with hemophilia A. Nat Med. 1999
Sep;5(9):1044-7.

37. Ponomarenko NA, Vorobiev, II, Alexandrova ES, Reshetnyak AV, Telegin GB,
Khaidukov SV, Avalle B, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov
AG. Induction of a protein-targeted catalytic response in autoimmune prone mice:
antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry. 2006 Jan
10;45(1):324-30.

38. Song Y, Myers R, Mehl F, Murphy L, Brooks B, Wilson JM, Kadl A, Woodfolk J,
Zeichner SL. ACE-2-like enzymatic activity is associated with immunoglobulin in
COVID-19 patients. mBio. 2024 Apr 10;15(4):e0054124. PMC11005375

39. Canderan G, Muehling LM, Kadl A, Ladd S, Bonham C, Cross CE, Lima SM, Yin
X, Sturek JM, Wilson JM, Keshavarz B, Bryant N, Murphy DD, Cheon IS, McNamara
CA, Sun J, Utz PJ, Dolatshahi S, Irish JM, Woodfolk JA. Distinct Type 1 Immune
Networks Underlie the Severity of Restrictive Lung Disease after COVID-19. bioRxiv.
2024:2024.04.03.587929.

40. Keshavarz B, Wiencek JR, Workman LJ, Straesser MD, Muehling LM, Canderan
G, Drago F, Bonham CA, Sturek JM, Ramani C, McNamara CA, Woodfolk JA, Kadl A,
Platts-Mills TAE, Wilson JM. Quantitative Measurement of IgG to Severe Acute
Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP. Int Arch Allergy
Immunol. 2021;182(5):417-24. PMC8018212

41. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L,
Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
ACE2 receptor. Nature. 2020 2020/05/01;581(7807):215-20.
691
692